Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_provenance.
- NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_assertion description "[Po-husk, apart from lowering LDL-C, also reduced TG, TG related to certain gene variants, TC, Apo B-100, oxLDL, insulin-resistance and systolic BP in mild-moderate hypercholesterolaemic individuals. Thus, the target patients to receive Po-husk would be those who present a cluster of various CVD risk factors, such as metabolic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_provenance.
- NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_assertion evidence source_evidence_literature NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_provenance.
- NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_assertion SIO_000772 20413122 NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_provenance.
- NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_assertion wasDerivedFrom gad-20130706 NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_provenance.
- NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_assertion wasGeneratedBy ECO_0000203 NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_provenance.
- gad-20130706 importedOn "2013-07-06" NP85816.RArQ9yD4Euq6px3pBymdvjh3GUGyjLHMsRwahSkXzgCic130_provenance.